Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Myelodysplastic syndrome in Tanzania; The current status of management

Eunice Shija, Koga Luhulla, primus ewald, William Mawalla, yonazi Mbonea, Srinivas Devarakonda, Yvonne Efebera

Blood (2025) 146 (Supplement 1): 7397.

https://doi.org/10.1182/blood-2025-7397

Published: 2025

Journal Articles

The impact of Duffy genotype on progression-free survival (PFS) with lenalidomide, Bortezomib, and dexamethasone (RVd) alone or RVd plus autologous stem cell transplantation (ASCT) and continuous R maintenance in patients (pts) with newly diagnosed multiple myeloma (NDMM): Updated subgroup analysis of the phase 3 DETERMINATION trial

Blood (2025) 146 (Supplement 1): 1033.

https://doi.org/10.1182/blood-2025-1033

Published: 2025

Journal Articles

Impact of race and socioeconomics on access to T-cell engaging therapy in US patients with relapsed/refractory multiple myeloma (RRMM)

Yvonne Efebera, Yelak Biru, Jeff O'Donnell, Kevin Brigle, Rebecca Davies, Anthony Greenwood, Jack Watkins, Katie Quinn, Isabel Perez-Cruz, James Farrell, Sikander Ailawadhi

Blood (2025) 146 (Supplement 1): 2813.

https://doi.org/10.1182/blood-2025-2813

Published: 2025

Journal Articles

Upstream integration of implementation planning in clinical trials through the blood and marrow transplant clinical trials network

Anna Desalvo, Brittany Ragon, Neel Bhatt, Betty K. Hamilton, Azra Borogovac, Mary Horowitz, Nandita Khera, Mark Juckett, Steven Devine, Christopher Dandoy, Alla Keyzner, Yvonne Efebera, John Plastaras, Mitchell Horwitz, Sarah Wall, Valerie Stewart, Mykala Heuer, Todd Molfenter

Blood (2025) 146 (Supplement 1): 7913.

https://doi.org/10.1182/blood-2025-7913

Published: 2025

Journal Articles

Efficacy and safety of frail adults treated with ciltacabtagene autoleucel in the real-world: A CIBMTR analysis

Blood (2025) 146 (Supplement 1): 133.

https://doi.org/10.1182/blood-2025-133

Published: 2025

Journal Articles

Cardiac risk factors and cardiac events in patients with newly diagnosed amyloid light chain (AL) amyloidosis from the Phase 2 aquarius study of daratumumab (DARA) plus bortezomib, cyclophosphamide, and dexamethasone (D-VCd)

Vaishali Sanchorawala, Monique Minnema, Yvonne Efebera, Angela Dispenzieri, Ashutosh Wechalekar, Martha Grogan, Antoine Huart, Michael Rosenzweig, Brandon Blue, Faizi Jamal, Christopher Pericone, Sandra Vasey, Yuping Chen, Matteo Loi, NamPhuong Tran, Efstathios Kastritis

Blood (2025) 146 (Supplement 1): 691.

https://doi.org/10.1182/blood-2025-691

Published: 2025

Journal Articles

Curcumin and resveratrol sensitizes TP53 mutant acute myeloid leukemia (AML) cell lines to venetoclax-induced apoptosis

Merielle William, Prashant Trikha, Dmitriy Ovcharenko, John Myers, Michael Becker, Yvonne Efebera, Basem William

Blood (2025) 146 (Supplement 1): 6793.

https://doi.org/10.1182/blood-2025-6793

Published: 2025

Journal Articles

Infections in patients with relapsed refractory multiple myeloma receiving idecabtagene vicleucel therapy: A real-world analysis from CIBMTR

Muhammad Bilal Abid, Kitsada Wudhikarn, Qiran Ye, Michael Martens, Abu-Sayeef Mirza, Lohith Gowda, Srinivas Devarakonda, Yvonne Efebera, Zeinab El Boghdadly, Christopher Dandoy, Othman Akhtar, Temitope Oloyede, Christen Ebens, Joshua Hill, Hemant Murthy, Miguel-Angel Perales, Anna Huppler, Jeffery Auletta

Blood (2025) 146 (Supplement 1): 716.

https://doi.org/10.1182/blood-2025-716

Published: 2025

Journal Articles

Sickle cell trait does not cause “sickle cell crisis” leading to exertion-related death: a systematic review

Lachelle D. Weeks, Allecia M. Wilson, Rakhi P. Naik, Yvonne Efebera, M. Hassan Murad, Anjlee Mahajan, Patrick T. McGann, Madeleine Verhovsek, Angela C. Weyand, Ahmar U. Zaidi, Michael R. DeBaun, Chancellor Donald, Roger A. Mitchell

Blood (2025) 145 (13): 1345–1352.

https://doi.org/10.1182/blood.2024026899

Published: 2025

Includes: Supplemental data

Journal Articles

Phase 2 Study of Daratumumab (DARA) Plus Bortezomib, Cyclophosphamide, and Dexamethasone (D-VCd) in a Diverse Patient Population with Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis: Aquarius

Michael Rosenzweig, Yvonne Efebera, Efstathios Kastritis, Brandon Blue, Faizi Jamal, Monique C Minnema, Christopher Pericone, Sandra Vasey, Yuping Chen, Sonja Kotoulek, Bart Vandael, Joana Duran, Samer Khaled, NamPhuong Tran, Jessica Vermeulen, Vaishali Sanchorawala

Blood (2023) 142 (Supplement 1): 4785.

https://doi.org/10.1182/blood-2023-181953

Published: 2023

Journal Articles

Treatment Outcomes and Prognostic Factors with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in African American (AA) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial

Blood (2023) 142 (Supplement 1): 4762.

https://doi.org/10.1182/blood-2023-181032

Published: 2023

Journal Articles

Patient-Reported Outcomes of BMT CTN 1703: A Randomized Phase III Study for Gvhd Prophylaxis - a Quality of Life Evaluation

Blood (2023) 142 (Supplement 1): 897.

https://doi.org/10.1182/blood-2023-187859

Published: 2023

Journal Articles

Ibrutinib in Combination with Revlimid/Dexamethasone (Rd) in Relapsed/Refractory Multiple Myeloma (AFT-15)

Yvonne Efebera, Vera Jean Suman, Shira N. Dinner, Ashley E Rosko, John T Mckay, Peter Barth, Patrick Hagen, Saad Z Usmani, Paul G. Richardson, Jacob P. Laubach

Blood (2023) 142 (Supplement 1): 3340.

https://doi.org/10.1182/blood-2023-187296

Published: 2023

Journal Articles

Predictive Score for Utilization of Second Autologous Stem Cell Transplantation in Patients with Multiple Myeloma

Arti Vaishnav, Abdullah Khan, Qiuhong Zhao, Naresh Bumma, Francesca Cottini, Elvira Umyarova, Nidhi Sharma, Yvonne Efebera, Lynn O'Donnell, Ashley E Rosko, Sumithira Vasu, Marcos de Lima, Don Benson, Srinivas Devarakonda

Blood (2023) 142 (Supplement 1): 911.

https://doi.org/10.1182/blood-2023-184904

Published: 2023

Journal Articles

Exploring LAG-3 Expression in Multiple Myeloma Patients Following Autologous Stem Cell Transplant

Lucas Fabienne, PhD, Michael Pennell, PhD, Don M. Benson, Jr., MD PhD, Yvonne Efebera, MD, Maria Chaudhry, MD, Jennifer A. Woyach, MD, Xiangnan Guan, Zhang Suohui, Christin E Burd, PhD, Ashley E. Rosko, MD

Blood (2018) 132 (Supplement 1): 3434.

https://doi.org/10.1182/blood-2018-99-119577

Published: 2018

Journal Articles

Impact of Cytokine Release Syndrome on Outcomes after T-Cell Replete Peripheral Blood Haploidentical Donor Transplantation

Blood (2018) 132 (Supplement 1): 3357.

https://doi.org/10.1182/blood-2018-99-114100

Published: 2018

Journal Articles

The OP-104 Anchor Study: A Phase 1/2 Study of Safety and Efficacy of Melflufen and Dexamethasone in Combination with Either Bortezomib or Daratumumab in Patients with Rrmm; First Report on Phase 1 Data

Blood (2018) 132 (Supplement 1): 1967.

https://doi.org/10.1182/blood-2018-99-112983

Published: 2018

Journal Articles

Lenalidomide and Vorinostat Maintenance after Autologous Transplant in Multiple Myeloma- Long Term Follow-up

Nidhi Sharma, PhD MS, Nita Williams, BS, Ashley E. Rosko, MD, Don M. Benson, Jr., MD PhD, Maria Chaudhry, MD, Craig C Hofmeister, MD MPH, Douglas W. Sborov, MD MS, Yvonne Efebera, MD

Blood (2018) 132 (Supplement 1): 2155.

https://doi.org/10.1182/blood-2018-99-116460

Published: 2018

Journal Articles

Aryl Hydrocarbon Receptor (AHR) Antagonism As a Transformative, Dual-Mechanism Novel Therapy for Multiple Myeloma

Taylor Gonzalez, Evan C Catton, Ashley E. Rosko, MD, Yvonne Efebera, MD, Maria Chaudhry, MD, Francesca Cottini, MD, Bethany L Mundy-Bosse, PhD, Tiffany Hughes, BS, PhD, Don M. Benson, Jr., MD PhD

Blood (2018) 132 (Supplement 1): 1933.

https://doi.org/10.1182/blood-2018-99-117465

Published: 2018

Journal Articles

A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma

Don M. Benson, Jr, Craig C. Hofmeister, Swaminathan Padmanabhan, Attaya Suvannasankha, Sundar Jagannath, Rafat Abonour, Courtney Bakan, Pascale Andre, Yvonne Efebera, Jérôme Tiollier, Michael A. Caligiuri, Sherif S. Farag

Blood (2012) 120 (22): 4324–4333.

https://doi.org/10.1182/blood-2012-06-438028

Published: 2012

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Myelodysplastic syndrome in Tanzania; The current status of management

Impact of race and socioeconomics on access to T-cell engaging therapy in US patients with relapsed/refractory multiple myeloma (RRMM)

Upstream integration of implementation planning in clinical trials through the blood and marrow transplant clinical trials network

Efficacy and safety of frail adults treated with ciltacabtagene autoleucel in the real-world: A CIBMTR analysis

Cardiac risk factors and cardiac events in patients with newly diagnosed amyloid light chain (AL) amyloidosis from the Phase 2 aquarius study of daratumumab (DARA) plus bortezomib, cyclophosphamide, and dexamethasone (D-VCd)

Curcumin and resveratrol sensitizes TP53 mutant acute myeloid leukemia (AML) cell lines to venetoclax-induced apoptosis

Infections in patients with relapsed refractory multiple myeloma receiving idecabtagene vicleucel therapy: A real-world analysis from CIBMTR

Sickle cell trait does not cause “sickle cell crisis” leading to exertion-related death: a systematic review

Phase 2 Study of Daratumumab (DARA) Plus Bortezomib, Cyclophosphamide, and Dexamethasone (D-VCd) in a Diverse Patient Population with Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis: Aquarius

Treatment Outcomes and Prognostic Factors with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in African American (AA) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial

Patient-Reported Outcomes of BMT CTN 1703: A Randomized Phase III Study for Gvhd Prophylaxis - a Quality of Life Evaluation

Ibrutinib in Combination with Revlimid/Dexamethasone (Rd) in Relapsed/Refractory Multiple Myeloma (AFT-15)

Predictive Score for Utilization of Second Autologous Stem Cell Transplantation in Patients with Multiple Myeloma

Exploring LAG-3 Expression in Multiple Myeloma Patients Following Autologous Stem Cell Transplant

Impact of Cytokine Release Syndrome on Outcomes after T-Cell Replete Peripheral Blood Haploidentical Donor Transplantation

The OP-104 Anchor Study: A Phase 1/2 Study of Safety and Efficacy of Melflufen and Dexamethasone in Combination with Either Bortezomib or Daratumumab in Patients with Rrmm; First Report on Phase 1 Data

Lenalidomide and Vorinostat Maintenance after Autologous Transplant in Multiple Myeloma- Long Term Follow-up

Aryl Hydrocarbon Receptor (AHR) Antagonism As a Transformative, Dual-Mechanism Novel Therapy for Multiple Myeloma

A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only